CCM® Therapy
Impulse Dynamics is determined to improve the lives of people with heart failure and is the developer of the innovative Optimizer® CCM® Therapy delivery system. CCM Therapy is a breakthrough heart failure treatment proven to improve quality of life for heart failure patients. CCM Therapy is specifically designed to improve systolic contraction in an effort to deliver more oxygen-rich blood to the body. CCM Therapy is a safe and effective, minimally invasive treatment option for millions of heart failure patients who otherwise have few or no effective options available to them. Optimizer® is the first and only FDA-approved device in the U.S. or elsewhere for the delivery of CCM Therapy.
Our mission at Impulse Dynamics is to exceed the expectations of patients, clinicians, and caregivers alike by developing and providing cardiac contractility modulation. The company believes in fostering innovation, transparency, and accountability in our relentless efforts to expand global access to the benefits of CCM Therapy.
HRS 2021 - Cardiac Contractility Modulation - Optimizing the Treatment of Heart Failure with Device Therapy
This video features a Rhythm Theatre presentation from HRS 2021 that features Dr. Jagmeet Singh as the moderator and includes a faculty of Dr. Niraj Varma, Dr. Raul Weiss, and Prof. Jurgen Kuschyk. Dr. Varma (0:00 – 14:48) begins by discussing the mechanism of action of CCM Therapy - explaining how the therapy works in the myocardium at the cellular level. Dr. Weiss (14:50 – 31:15) details the cadence of clinical trials that led to the approval of CCM therapy, provides an update on the current Post Approval Study (PAS), and sheds light on the many new trials to come. Finally, Dr. Kuschyk (31:16 – 57:25) presents the results of a recently published prospective registry of over 500 patients followed for 3 years that have received CCM therapy. The clinical outcomes observed in this long term study deserve your attention!
- October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
